Cullinan Oncology, Inc.

Historical 13F Holders

Symbol
CGEM
CUSIP
230031106
All holders as of
Q2 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 230031106 since 12/18/2024, largest first.

Filer % of Class Filed
Biotechnology Value Fund L P 13G/A
10.0% 8/14/2026
Event 6/30/2026
Lynx1 Capital Management LP 13G/A
9.8% 11/14/2025
Event 9/30/2025
Price T Rowe Associates Inc /MD/ 13G 6.2% 8/14/2026
Event 6/30/2026
State Street Corp 13G 6.0% 8/7/2026
Event 6/30/2026
Kynam Capital Management, LP 13G
5.3% 3/4/2026
Event 12/31/2025
Under 5%, checked the "5 percent or less" box, or amended by a later filing (4)
James E. Flynn 13G/A
4.95% 11/13/2025
Event 9/30/2025
Franklin Resources, Inc. 13G/A
3.8% 10/31/2024
Event 9/30/2024
Citadel Advisors LLC 13G/A
3.4% 11/14/2025
Event 9/30/2025
Vanguard Group Inc 13G/A 0% 3/26/2026
Event 3/13/2026

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q3 4 4.48 k $68.7 k
2026 Q2 193 72.4 M $1.35 B
2026 Q1 179 65.6 M $931 M
2025 Q4 160 63.2 M $654 M
2025 Q3 149 61.1 M $363 M
2025 Q2 151 62.6 M $472 M
2025 Q1 154 64.7 M $490 M
2024 Q4 153 65.6 M $799 M
2024 Q3 146 65.0 M $1.09 B
2024 Q2 142 63.8 M $1.11 B
2024 Q1 120 41.7 M $711 M
2023 Q4 120 38.0 M $387 M
2023 Q3 112 38.3 M $346 M
2023 Q2 110 36.9 M $397 M
2023 Q1 107 32.3 M $330 M
2022 Q4 102 38.3 M $404 M
2022 Q3 104 37.0 M $475 M
2022 Q2 91 37.6 M $482 M
2022 Q1 85 36.9 M $386 M
2021 Q4 79 36.4 M $560 M
2021 Q3 68 33.9 M $762 M
2021 Q2 73 32.3 M $829 M
2021 Q1 71 31.3 M $1.30 B